Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?
Open Access
- 9 March 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 10, 820259
Abstract
Bronchopulmonary Dysplasia (BPD) is a multifactorial disease affecting over 35% of extremely preterm infants born each year. Despite the advances made in understanding the pathogenesis of this disease over the last five decades, BPD remains one of the major causes of morbidity and mortality in this population, and the incidence of the disease increases with decreasing gestational age. As inflammation is one of the key drivers in the pathogenesis, it has been targeted by majority of pharmacological and non-pharmacological methods to prevent BPD. Most extremely premature infants receive a myriad of medications during their stay in the neonatal intensive care unit in an effort to prevent or manage BPD, with corticosteroids, caffeine, and diuretics being the most commonly used medications. However, there is no consensus regarding their use and benefits in this population. This review summarizes the available literature regarding these medications and aims to provide neonatologists and neonatal providers with evidence-based recommendations.Keywords
This publication has 306 references indexed in Scilit:
- Role of EC-SOD Overexpression in Preserving Pulmonary Angiogenesis Inhibited by Oxidative StressPLOS ONE, 2012
- Maternal Dietary DHA Supplementation to Improve Inflammatory Outcomes in the Preterm InfantAdvances in Nutrition, 2012
- Prediction of Bronchopulmonary Dysplasia by Postnatal Age in Extremely Premature InfantsAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSCCell Communication and Signaling, 2011
- S -Nitrosylation in Cardiovascular SignalingCirculation Research, 2010
- Airway Delivery of Mesenchymal Stem Cells Prevents Arrested Alveolar Growth in Neonatal Lung Injury in RatsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injuryRespiratory Research, 2009
- Impact of Postnatal Corticosteroid Use on Neurodevelopment at 18 to 22 Months' Adjusted Age: Effects of Dose, Timing, and Risk of Bronchopulmonary Dysplasia in Extremely Low Birth Weight InfantsPediatrics, 2009
- One-Year Respiratory Outcomes of Preterm Infants Enrolled in the Nitric Oxide (to Prevent) Chronic Lung Disease TrialThe Journal of Pediatrics, 2008
- Azithromycin in the extremely low birth weight infant for the prevention of Bronchopulmonary Dysplasia: a pilot studyRespiratory Research, 2007